Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neurocrine Biosciences (NBIX) Depreciation and Depletion (2019 - 2025)

Historic Depreciation and Depletion for Neurocrine Biosciences (NBIX) over the last 6 years, with Q4 2025 value amounting to $6.4 million.

  • Neurocrine Biosciences' Depreciation and Depletion rose 322.58% to $6.4 million in Q4 2025 from the same period last year, while for Dec 2025 it was $26.0 million, marking a year-over-year increase of 1063.83%. This contributed to the annual value of $26.0 million for FY2025, which is 1063.83% up from last year.
  • According to the latest figures from Q4 2025, Neurocrine Biosciences' Depreciation and Depletion is $6.4 million, which was up 322.58% from $6.7 million recorded in Q3 2025.
  • In the past 5 years, Neurocrine Biosciences' Depreciation and Depletion registered a high of $6.7 million during Q3 2025, and its lowest value of $2.5 million during Q1 2021.
  • Over the past 4 years, Neurocrine Biosciences' median Depreciation and Depletion value was $5.6 million (recorded in 2024), while the average stood at $5.4 million.
  • Its Depreciation and Depletion has fluctuated over the past 5 years, first skyrocketed by 5238.1% in 2024, then crashed by 156.25% in 2025.
  • Neurocrine Biosciences' Depreciation and Depletion (Quarter) stood at $2.5 million in 2021, then surged by 96.0% to $4.9 million in 2023, then increased by 26.53% to $6.2 million in 2024, then increased by 3.23% to $6.4 million in 2025.
  • Its Depreciation and Depletion was $6.4 million in Q4 2025, compared to $6.7 million in Q3 2025 and $6.3 million in Q2 2025.